骨髓纤维化临床表型的生物学驱动因素
骨髓纤维化(MF)在生物学和临床上异质性很大,存在骨髓衰竭/细胞减少型与骨髓增殖型两个极端表型。细胞减少型在原发MF中高发、血细胞计数低、预后较差;增殖型常与继发MF相关、贫血轻、输血需求少。体细胞驱动突变、等位基因负荷及非驱动突变影响这些表型差异、预后和对JAK2抑制剂的反应。固有免疫失调经myddsome-IRAK-NFκB轴促进细胞减少型MF表型,为新型治疗提供机会。
要点
- MF存在细胞减少型与骨髓增殖型两个表型极端,细胞减少型在原发MF中高发且预后较差
- 驱动突变、等位基因负荷及非驱动突变共同影响表型、预后和对JAK2抑制剂的反应
- 固有免疫失调经myddsome-IRAK-NFκB轴促进细胞减少型MF表型
核心结论
- MF的生物学和临床异质性体现在细胞减少型与骨髓增殖型两个表型极端,细胞减少型患者结局相对更差。
- 固有免疫失调经myddsome-IRAK-NFκB轴促进细胞减少型MF表型,为新型治疗提供机会。
研究设计与样本
- 综述,总结MF疾病谱的生物学与临床特征及相关治疗考虑。
主要发现
- 细胞减少型表型在原发MF中高发,以血细胞计数低为特征。
- 骨髓增殖型表型通常与继发MF相关、贫血轻、输血支持需求少、血小板正常至轻度减少。
- 细胞减少型患者结局相对更差,且因细胞减少本身加重而常难以治疗。
关键数值与推荐
- 细胞减少型表型特征为血细胞计数低,在原发MF中高发。
- 骨髓增殖型表型通常与继发MF相关,伴轻度贫血、输血支持需求少、血小板正常至轻度减少。
临床怎么用
- 综述讨论MF疾病谱相关的治疗考虑,包括JAK2抑制剂反应受驱动及非驱动突变影响。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Myelofibrosis (MF) is a myeloproliferative disorder that exhibits considerable biological and clinical heterogeneity. At the two ends of the disease spectrum are the myelodepletive or cytopenic phenotype and the myeloproliferative phenotype. The cytopenic phenotype has a high prevalence in primary MF (PMF) and is characterized by low blood counts. The myeloproliferative phenotype is typically associated with secondary MF (SMF), mild anemia, minimal need for transfusion support, and normal to mild thrombocytopenia. Differences in somatic driver mutations and allelic burden, as well as the acquisition of non-driver mutations further influences these phenotypic differences, prognosis, and response to therapies such as JAK2 inhibitors. The outcome of patients with the cytopenic phenotype are comparatively worse and frequently pose a challenge to treat given the inherent exacerbation of cytopenias. Recent data indicate that an innate immune deregulated state that hinges on the myddosome-IRAK-NFκB axis favors the cytopenic myelofibrosis phenotype and offers opportunity for novel treatment approaches. We will review the biological and clinical features of the MF disease spectrum and associated treatment considerations.
引用
- Mascarenhas J, Gleitz HFE, Chifotides HT, et al. Biological drivers of clinical phenotype in myelofibrosis. Leukemia. 2022. PMID: 36434065. doi:10.1038/s41375-022-01767-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。